All Updates

All Updates

icon
Filter
Partnerships
Genesis Therapeutics collaborates with Roche’s Subsidiary Genentech
AI Drug Discovery
Oct 18, 2020
This week:
Regulation/policy
UK to regulate BNPL offerings by 2026
Buy Now, Pay Later
Yesterday
M&A
Stripe to acquire stablecoin platform Bridge for USD 1 billion
FinTech Infrastructure
Yesterday
Partnerships
Intuitive AI partner with Moda Center to implement Oscar Sort recycling technology
Waste Recovery & Management Tech
Yesterday
Management news
Funding
Minze Health raises USD 5.3 million in funding for product and market expansion; appoints new VP
Preventive Healthcare
Yesterday
Partnerships
Firefly Aerospace partners with True Anomaly for Space Force rapid-response mission launches
Space Travel and Exploration Tech
Yesterday
Funding
zkPass raises USD 12.5 million in Series A funding
Enterprise Blockchain Solutions
Yesterday
Partnerships
Ontada partners with Microsoft to process unstructured oncology data using Azure AI
Clinical Trial Technology
Yesterday
Product updates
Burcon unveils canola protein isolate for egg replacement
Plant-based Dairy & Egg
Yesterday
Product updates
Bene Meat Technologies produces first cultivated burger at parity with premium beef
Cell-cultured Meat
Yesterday
Geographic expansion
Regulation/policy
The Better Meat Co. expands to Asia with Singapore approval for Rhiza mycoprotein
Plant-based Meat
Yesterday
AI Drug Discovery

AI Drug Discovery

Oct 18, 2020

Genesis Therapeutics collaborates with Roche’s Subsidiary Genentech

Partnerships

  • Genesis Therapeutics, an AI drug discovery startup, has entered into a collaboration with Genentech, a wholly-owned biotechnology subsidiary of Roche Group, to support identification of new drug candidates across a range of diseases. 

  • Genentech will gain access to Genesis’ AI platform and other neural network algorithms that aim to predict how well molecules bind with moving protein chains.  This will help the company develop therapeutics for targets previously classified as undruggable. 

  • Genesis will receive an undisclosed amount as an upfront payment. The company may also receive preclinical, clinical and regulatory milestone payments and royalties on sales of therapeutics developed through the collaboration. 

  • Founded in 2019, Genesis Therapeutics is a Stanford University spinout company that claims to offer low cost AI drug discovery services. It secured seed funding of USD 4.1 million in November 2019.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.